Latest Financial Performance News

Scentre Group has successfully tendered 89% of its US$1.312 billion 2030 subordinated notes and plans to redeem the remainder, boosting liquidity to A$3.2 billion while maintaining 4% growth targets for 2026.

Matsa Resources has kicked off a major diamond drilling campaign at Fortitude North targeting up to 1.85 million ounces of gold while reporting robust $28.7 million gold sales and $6.1 million EBITDA from the Devon Pit Gold Mine.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Beonic Limited’s Q3 FY26 results highlight a tripling of EBITDA margin to 15.8%, driven by operational leverage and gross margin expansion, while the Moroccan Airports rollout stays on track for full delivery by June 2026.

Pointerra Limited delivered a 214% jump in Q3 FY26 customer receipts to A$2.2 million, driven by milestone invoicing and new Tier 1 utility contracts, edging closer to operating cashflow breakeven.

Titomic Limited is gearing up for a strategic shift to the US with a planned redomicile in H2 2026, while clinching major contracts across aerospace, defense, and rail sectors and achieving critical certifications that underpin its manufacturing ambitions.

Electro Optic Systems (ASX: EOS) reported a 13% increase in contract backlog to A$518 million in Q1 2026, driven by multiple major defence orders and the opening of a new Singapore facility. The company’s cash position remains strong despite a $4 million ASIC penalty.

Metals X reported its fourth highest quarterly tin production at Renison with robust financials despite rising unit costs, while progressing the Rentails project and maintaining a strong cash position.

hipages Group (ASX:HPG) has kicked off an on-market buy-back of up to 10% of its shares, signalling confidence in its undervalued stock amid strong cash flow and growth.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.

Vection Technologies has reported its third straight quarter of positive operating cash flow, driven by a $30 million Defence order book and a surge in AI contracts worth $4 million across multiple sectors.